Complete Filing Data
Cadrenal Therapeutics, Inc. reported Stockholders Equity of $2.74 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Cadrenal Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Income Loss | -$13.5M | -$11.0M | -$7.6M | -$2.7M |
| Operating Expenses | $13.5M | $11.0M | $7.6M | $2.7M |
| Net Income Loss | -$13.2M | -$10.7M | -$8.4M | -$6.7M |
| General And Administrative Expense | $9.4M | $6.8M | $3.5M | $2.3M |
| Research And Development Expense | $4.1M | $4.2M | $4.1M | $392.9K |
| Nonoperating Income Expense | $223.8K | $309.3K | -$724.2K | -$4.0M |
| Research And Development Expense Excluding Acquired In Process Cost | $392.9K | |||
| Interest Expense | $40.2K | |||
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$6.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income Loss | -$2.7M | -$3.7M | -$3.9M | -$2.5M | -$2.5M | -$1.8M | -$1.1M | -$1.0M | -$4.2M | -$972.8K | -$482.3K | -$170.5K |
| Operating Expenses | $2.7M | $3.7M | $3.9M | $2.5M | $2.5M | $1.8M | $1.1M | $1.0M | $4.2M | $972.8K | $482.3K | $170.5K |
| Net Income Loss | -$2.7M | -$3.7M | -$3.8M | -$2.4M | -$2.4M | -$1.7M | -$1.0M | -$1.0M | -$5.2M | -$1.0M | -$502.1K | -$176.6K |
| General And Administrative Expense | $2.0M | $2.7M | $2.3M | $1.7M | $1.2M | $1.1M | $898.1K | $784.6K | $964.7K | $915.9K | $280.1K | $152.7K |
| Research And Development Expense | $688.5K | $1.1M | $1.7M | $784.6K | $1.3M | $629.0K | $243.9K | $241.0K | $3.2M | $56.4K | ||
| Nonoperating Income Expense | $48.1K | $67.0K | $82.6K | $52.1K | $73.6K | $92.3K | $106.1K | $23.2K | -$973.3K | -$53.3K | -$19.8K | |
| Research And Development Expense Excluding Acquired In Process Cost | $241.0K | $3.2M | $202.2K | $17.9K | ||||||||
| Interest Expense | $3.5K | $13.5K | $6.4K | $2.1K | ||||||||
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$1.0M | -$5.2M | -$502.1K | -$176.6K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $2.7M | $7.4M | $7.7M | -$5.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $4.0M | $10.0M | $8.4M | $32.6K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$6.0M | $1.6M | $8.4M | $32.6K |
| Retained Earnings Accumulated Deficit | -$39.0M | -$25.7M | -$15.1M | -$6.7M |
| Property Plant And Equipment Net | $5.2K | $6.9K | $2.3K | $1.0K |
| Other Assets Noncurrent | $2.2K | $3.8K | $3.8K | $6.0K |
| Liabilities Current | $1.6M | $2.7M | $826.9K | $1.3M |
| Liabilities And Stockholders Equity | $4.3M | $10.1M | $8.5M | $778.2K |
| Liabilities | $1.6M | $2.7M | $826.9K | $6.3M |
| Common Stock Value | $2.3K | $1.8K | $868.00 | $8.2K |
| Assets Current | $4.3M | $10.1M | $8.5M | $727.6K |
| Assets | $4.3M | $10.1M | $8.5M | $778.2K |
| Accrued Liabilities Current | $937.3K | $1.2M | $638.2K | $863.6K |
| Accounts Payable Current | $650.7K | $1.5M | $167.3K | $404.9K |
| Operating Lease Right Of Use Asset | $21.0K | $43.6K | ||
| Operating Lease Liability Current | $21.4K | $22.3K | ||
| Amortization Of Debt Discount Premium | $13.6K | $66.9K | ||
| Cash And Cash Equivalents At Carrying Value | $4.0M | $10.0M | $32.6K | |
| Deferred Costs Current | $106.3K | $14.4K | ||
| Prepaid Expense And Other Assets Current | $200.1K | $42.3K | $52.4K | |
| Operating Lease Liability Noncurrent | $21.4K | |||
| Interest Receivable Current | $5.1K | $38.2K | $37.2K | |
| Gains Losses On Extinguishment Of Debt | -$740.1K | |||
| Repayments Of Related Party Debt | $250.0K | |||
| Stock Issued During Period Value Purchase Of Assets | $3.0M | |||
| Cash Equivalents At Carrying Value | ||||
| Additional Paid In Capital Common Stock | $1.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $2.7M | $4.3M | $6.1M | $3.4M | $4.0M | $6.2M | $8.7M | $3.2M | $4.1M | -$1.2M | -$670.8K | -$169.1K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $3.9M | $5.6M | $7.3M | $4.4M | $5.0M | $6.6M | $9.1M | $3.2M | $4.0M | $103.1K | $59.6K | $462.3K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$2.7M | -$1.8M | $4.0M | $462.3K | ||||||||||
| Retained Earnings Accumulated Deficit | -$35.9M | -$33.2M | -$29.6M | -$21.5M | -$19.1M | -$16.7M | -$13.9M | -$12.9M | -$11.9M | |||||
| Property Plant And Equipment Net | $5.7K | $4.3K | $4.7K | $814.00 | $1.2K | $1.7K | $2.9K | $3.5K | $823.00 | |||||
| Other Assets Noncurrent | $2.2K | $2.2K | $3.8K | $3.8K | $3.8K | $3.8K | $3.8K | $3.8K | $3.8K | |||||
| Liabilities Current | $1.4M | $1.7M | $1.8M | $1.3M | $1.5M | $856.3K | $563.6K | $374.3K | $401.6K | |||||
| Liabilities And Stockholders Equity | $4.1M | $6.0M | $8.0M | $4.7M | $5.5M | $7.0M | $9.3M | $3.6M | $4.5M | |||||
| Liabilities | $1.4M | $1.7M | $1.8M | $1.3M | $1.5M | $856.3K | $565.8K | $383.1K | $416.8K | |||||
| Common Stock Value | $2.1K | $2.0K | $1.9K | $1.2K | $16.0K | $16.0K | $13.0K | $11.7K | $11.7K | |||||
| Assets Current | $4.1M | $6.0M | $7.9M | $4.7M | $5.4M | $7.0M | $9.3M | $3.5M | $4.4M | |||||
| Assets | $4.1M | $6.0M | $8.0M | $4.7M | $5.5M | $7.0M | $9.3M | $3.6M | $4.5M | |||||
| Accrued Liabilities Current | $738.5K | $783.9K | $561.8K | $767.9K | $696.6K | $440.8K | $396.9K | $272.1K | $258.9K | |||||
| Accounts Payable Current | $614.1K | $895.6K | $1.3M | $496.8K | $759.5K | $400.4K | $141.7K | $78.1K | $119.6K | |||||
| Operating Lease Right Of Use Asset | $2.2K | $8.7K | $14.9K | $26.9K | $32.6K | $38.2K | ||||||||
| Operating Lease Liability Current | $2.2K | $8.8K | $15.2K | $25.0K | $24.1K | $23.2K | ||||||||
| Amortization Of Debt Discount Premium | $13.6K | $2.5K | ||||||||||||
| Cash And Cash Equivalents At Carrying Value | $3.9M | $5.6M | $7.3M | $6.6M | $8.4M | $9.1M | ||||||||
| Deferred Costs Current | $90.8K | $23.9K | $8.5K | $116.9K | $171.4K | $672.3K | ||||||||
| Prepaid Expense And Other Assets Current | $116.0K | $358.4K | $575.6K | |||||||||||
| Operating Lease Liability Noncurrent | $2.2K | $8.8K | $15.2K | |||||||||||
| Interest Receivable Current | $12.8K | $19.0K | $24.7K | |||||||||||
| Gains Losses On Extinguishment Of Debt | -$740.1K | |||||||||||||
| Repayments Of Related Party Debt | $250.0K | |||||||||||||
| Stock Issued During Period Value Purchase Of Assets | $3.0M | |||||||||||||
| Cash Equivalents At Carrying Value | $3.2M | $4.0M | $32.6K | |||||||||||
| Additional Paid In Capital Common Stock | $23.1M | $22.9M | $22.8M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Net Cash Provided By Used In Financing Activities | $6.6M | $9.0M | $11.9M | $1.2M |
| Increase Decrease In Prepaid Expense | $157.9K | -$10.2K | $29.7K | $22.7K |
| Increase Decrease In Accounts Payable | -$851.8K | $1.3M | -$237.6K | $404.9K |
| Increase Decrease In Deferred Charges | $91.9K | $14.4K | -$672.3K | $672.3K |
| Share Based Compensation | $1.9M | $1.4M | $710.4K | $928.0K |
| Increase Decrease In Other Operating Assets | -$1.6K | -$2.2K | $6.0K | |
| Increase Decrease In Accrued Liabilities | -$244.2K | $543.3K | -$225.6K | $863.6K |
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $1.8M | $747.0K | ||
| Proceeds From Warrant Exercises | $298.00 | $250.0K | ||
| Payments To Acquire Property Plant And Equipment | $5.1K | $6.5K | $3.3K | $2.3K |
| Net Cash Provided By Used In Investing Activities | -$5.1K | -$6.5K | -$3.3K | -$2.3K |
| Proceeds From Issuance Of Common Stock | $4.9M | $5.1M | $8.0K | |
| Increase Decrease In Accrued Interest Receivable Net | -$33.1K | $905.00 | $37.2K | -$40.2K |
| Increase Decrease In Other Accrued Liabilities | $863.6K | |||
| Payments Of Stock Issuance Costs | $337.64B | |||
| Proceeds From Convertible Debt | $1.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$4.6M | -$1.8M | -$1.4M | -$43.7K | ||||
| Net Cash Provided By Used In Financing Activities | $2.0M | $298.00 | $5.4M | $506.0K | ||||
| Increase Decrease In Prepaid Expense | $533.3K | $212.4K | $279.9K | $2.2K | ||||
| Increase Decrease In Accounts Payable | -$224.1K | $233.1K | -$285.3K | $15.1K | ||||
| Increase Decrease In Deferred Charges | -$6.0K | $167.8K | -$672.3K | |||||
| Share Based Compensation | $548.8K | $162.7K | $286.4K | |||||
| Increase Decrease In Other Operating Assets | -$2.2K | $1.1K | ||||||
| Increase Decrease In Accrued Liabilities | -$619.7K | -$197.4K | -$604.9K | |||||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $473.4K | $489.1K | $518.9K | $195.6K | $193.1K | $162.7K | ||
| Proceeds From Warrant Exercises | $298.00 | $250.0K | ||||||
| Payments To Acquire Property Plant And Equipment | $3.3K | |||||||
| Net Cash Provided By Used In Investing Activities | -$3.3K | |||||||
| Proceeds From Issuance Of Common Stock | $2.1M | $5.4M | ||||||
| Increase Decrease In Accrued Interest Receivable Net | -$13.5K | -$8.3K | ||||||
| Increase Decrease In Other Accrued Liabilities | -$604.9K | $117.1K | ||||||
| Payments Of Stock Issuance Costs | $35.6K | $63.7K | $85.3K | $107.8K | ||||
| Proceeds From Convertible Debt | $498.5K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Diluted Shares Outstanding | 2.0M | 1.2M | 899.5K | 7.9M |
| Weighted Average Number Of Shares Outstanding Basic | 2.0M | 1.2M | 899.5K | 7.9M |
| Earnings Per Share Diluted | $-6.64 | $-8.73 | $-9.29 | $-0.85 |
| Earnings Per Share Basic | $-6.64 | $-8.73 | $-9.29 | $-0.85 |
| Common Stock Shares Outstanding | 2.3M | 1.8M | 868.2K | 8.2M |
| Common Stock Shares Issued | 2.3M | 1.8M | 868.2K | 8.2M |
| Common Stock Shares Authorized | 75.0M | 75.0M | 75.0M | 75.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 7.5M | 7.5M | 7.5M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Diluted Shares Outstanding | 2.0M | 2.0M | 1.8M | 1.1M | 1.1M | 1.1M | 1.0M | 11.7M | 10.8M | 8.0M | 7.7M | 7.5M |
| Weighted Average Number Of Shares Outstanding Basic | 2.0M | 2.0M | 1.8M | 1.1M | 1.1M | 1.1M | 1.0M | 11.7M | 10.8M | 8.0M | 7.7M | 7.5M |
| Earnings Per Share Diluted | $-1.31 | $-1.87 | $-2.09 | $-2.18 | $-2.24 | $-1.56 | $-1.01 | $-0.09 | $-0.48 | $-0.13 | $0.07 | $-0.02 |
| Earnings Per Share Basic | $-1.31 | $-1.87 | $-2.09 | $-2.18 | $-2.24 | $-1.56 | $-1.01 | $-0.09 | $-0.48 | $-0.13 | $-0.07 | $-0.02 |
| Common Stock Shares Outstanding | 2.1M | 2.0M | 1.9M | 1.2M | 16.0M | 16.0M | 13.0M | 11.7M | 11.7M | |||
| Common Stock Shares Issued | 2.1M | 2.0M | 1.9M | 1.2M | 16.0M | 16.0M | 13.0M | 11.7M | 11.7M | |||
| Common Stock Shares Authorized | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | 75.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Authorized | 7.5M | 7.5M | 7.5M | 7.5M | 7.5M | |||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Depreciation | $6.9K | $1.9K | $2.0K | $1.3K |
| Investment Income Interest And Dividend | $223.8K | $309.3K | $249.1K | $21.00 |
| Additional Paid In Capital | $41.7M | $33.2M | $22.8M | |
| Stock Issued During Period Value New Issues | $4.6M | $4.8M | $5.4M | $8.0K |
| Fair Value Adjustment Of Warrants | $216.1K | $3.9M | ||
| Stock Issued During Period Value Issued For Services | $133.4K | $672.0K | $108.3K | |
| Prepaid Expense Current | $22.7K | |||
| Stock Issued During Period Value Restricted Stock Award Gross | $928.0K | |||
| Stock Issued During Period Value Stock Options Exercised | $48.0K | $250.0K | ||
| Amortization Of Financing Costs And Discounts | $66.9K | |||
| Other Noncash Income Expense | $352.00 | -$292.00 | ||
| Stock Issued During Period Value Conversion Of Convertible Securities | $1.1M | |||
| Issuance Of Shares To Settle Asset Purchase Agreement | 3.0M | |||
| Stock Issued During Period Value Issuance Of Common Shares From Exercise Of Prefunded Warrants | 298.00 | |||
| Stock Issued1 | $1.1M | $175.6K | ||
| Payment Of Financing And Stock Issuance Costs | $271.2K | $337.6K | ||
| Stock Issued During Period Value Other | -$6.5M | $175.6K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation | $401.00 | $401.00 | $5.5K | $407.00 | $470.00 | $597.00 | $597.00 | $597.00 | $190.00 | $506.00 | ||||
| Investment Income Interest And Dividend | $48.1K | $67.0K | $82.6K | $52.1K | $73.6K | $92.3K | $106.1K | $23.2K | $3.00 | |||||
| Additional Paid In Capital | $38.7M | $37.5M | $35.7M | $24.9M | $22.7M | $16.1M | $15.9M | $1.2M | ||||||
| Stock Issued During Period Value New Issues | $632.4K | $1.5M | $5.4M | $450.00 | $7.5K | |||||||||
| Fair Value Adjustment Of Warrants | $216.1K | $21.3K | $5.0K | $1.5K | ||||||||||
| Stock Issued During Period Value Issued For Services | $103.5K | $29.9K | $104.4K | $108.3K | ||||||||||
| Prepaid Expense Current | $191.7K | $234.9K | $293.8K | $89.7K | $168.6K | $289.3K | $410.9K | |||||||
| Stock Issued During Period Value Restricted Stock Award Gross | $98.9K | $113.7K | $286.4K | $478.7K | ||||||||||
| Stock Issued During Period Value Stock Options Exercised | $16.0K | $32.0K | $250.0K | |||||||||||
| Amortization Of Financing Costs And Discounts | $13.6K | $18.5K | $8.3K | $2.5K | ||||||||||
| Other Noncash Income Expense | $105.00 | |||||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $1.1M | |||||||||||||
| Issuance Of Shares To Settle Asset Purchase Agreement | 3.0M | |||||||||||||
| Stock Issued During Period Value Issuance Of Common Shares From Exercise Of Prefunded Warrants | 298.00 | |||||||||||||
| Stock Issued1 | $1.1M | |||||||||||||
| Payment Of Financing And Stock Issuance Costs | $85.3K | |||||||||||||
| Stock Issued During Period Value Other | $1.5M |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.